Although the mechanism underlying the direct anticancer effect of AIMs on tumor cells is not completely understood, it is known that AIMs modulate the activity of several cancer-related proteins, including cyclin D1 [12;23], CDKN1A (p21) [23], JAK1 and STAT3 [24;25], HER2 [26], and nuclear factor kappa B (NF-κB) [27–29]. Here, CDKN1A is linked to neoplasm.